We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$465M
Cap. Flow %
-8.83%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDNA icon
126
CareDx
CDNA
$1.84B
– –
-827,600
Closed -$29.8M
DVAX
127
DELISTED
Dynavax Technologies
DVAX
– –
-583,500
Closed -$2.33M
FOLD
128
DELISTED
Amicus Therapeutics
FOLD
– –
-518,309
Closed -$6.47M
GILD icon
129
CALL
Gilead Sciences
GILD
$166B
– –
-100,000
Closed -$6.76M
GNFT
130
DELISTED
Genfit
GNFT
– –
-1,125,607
Closed -$22.2M
ILMN icon
131
Illumina
ILMN
$29B
– –
-144,126
Closed -$51.6M
PFE icon
132
PUT
Pfizer
PFE
$144B
– –
-263,500
Closed -$10.8M
PRQR icon
133
ProQR Therapeutics
PRQR
$241M
– –
-1,382,502
Closed -$12.6M
RYTM icon
134
Rhythm Pharmaceuticals
RYTM
$7.34B
– –
-787,300
Closed -$17.3M
SPY icon
135
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
– –
-100,000
Closed -$29.3M
STOK icon
136
Stoke Therapeutics
STOK
$1.8B
– –
-130,000
Closed -$3.79M
SYK icon
137
Stryker
SYK
$135B
– –
-54,000
Closed -$11.1M
TAK icon
138
CALL
Takeda Pharmaceutical
TAK
$56.7B
– –
-1,000,000
Closed -$17.7M
VTRS icon
139
Viatris
VTRS
$20.7B
– –
-1,373,305
Closed -$26.1M
MRNS
140
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-99,525
Closed -$1.65M
VRAY
141
DELISTED
ViewRay, Inc.
VRAY
– –
-5,149,019
Closed -$45.4M
CLVS
142
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,913,234
Closed -$28.4M
ENDP
143
DELISTED
Endo International plc
ENDP
– –
-6,165,464
Closed -$25.4M
FLXN
144
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-89,919
Closed -$1.11M
IMMU
145
DELISTED
Immunomedics Inc
IMMU
– –
-818,200
Closed -$11.3M
MDCO
146
DELISTED
Medicines Co
MDCO
– –
-151,515
Closed -$5.53M
NVTR
147
DELISTED
Nuvectra Corporation Common Stock
NVTR
– –
-350,000
Closed -$1.17M
RLM
148
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
– –
-1,021,484
Closed -$2.87M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $465M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.